After researching 16 thousand people, Pfizer announced that the COVID-19 vaccine, developed jointly with BioNTech, was 95.6% effective in the third dose.
The US-based pharmaceutical company Pfizer, together with the German biotechnology giant BioNTech, continues to conduct research on the COVID-19 vaccine, which is a hope for the whole world. While discussing the effects and necessity of the third dose on the world’s agenda, Pfizer a new study to prove the effect of the third dose performed.
In this study, in which 10 thousand people aged 16 and over participated, the third dose of vaccine was administered 11 months after the second dose. According to Pfizer’s statements In this study, the mean age was 52 years. The success rate achieved is 95.6%.
All participants were previously vaccinated with two doses
The research in question included participants who had previously received 2 doses of COVID-19 vaccine. Just like Pfizer’s previous research, some with placebo doses, some with real COVID-19 vaccines given.
Stating that one third of the people participating in the research are 65 years old, Pfizer said, “reinforcementthe third dose of vaccine, referred to as ” It has an effect of 95.6% expressed.
Source :
https://tr.sputniknews.com/20211021/research-pfizer-asisini-ucuncu-dozu-yuzde-956-oraninda-effective-1050046076.html